Effects of the "AI-TA" Mobile App With Intelligent Design on Psychological and Related Symptoms of Young Survivors of Breast Cancer: Randomized Controlled Trial.
Lulu Jiang, Jiehui Xu, Yanwei Wu...
https://pubmed.ncbi.nlm.nih.gov/38833298/Actively Recruiting
Led by Ege University · Updated on 2026-09-17
70
Participants Needed
1
Research Sites
1 weeks
Total Duration
Researchers are evaluating an artificial intelligence-supported mobile application designed to help women with breast cancer who are receiving chemotherapy for the first time. This randomized controlled trial aims to determine if the mobile app improves symptom management, boosts patients confidence in managing their symptoms self-efficacy, and enhances quality of life compared with standard care. The study will take place between June and December 2026 at two chemotherapy centers and involve 70 female participants. Participants will be randomly assigned to either use the AI-supported mobile application alongside their usual care or receive standard care alone. Those using the app will report their symptoms daily through their Android smartphones, receiving personalized, AI-generated recommendations for managing symptoms based on their reports. The app also offers educational content about breast cancer and treatment. Both groups will complete assessments at the start of chemotherapy, after the first chemotherapy cycle, and after the fourth cycle, which typically spans about 12 weeks. Throughout the study, participants will complete surveys measuring symptom burden, self-efficacy in managing chemotherapy symptoms, and quality of life using established questionnaires. Data collection will be performed by a dedicated researcher. This study monitors these outcomes over approximately 12 weeks to assess how the AI-supported app impacts patient well-being and symptom control compared to routine care.
CONDITIONS
Artificial Intelligence-supported Mobile Application for Patients With Breast Cancer
G
Gökhan Sezgin, PhD Candidate
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Ege University
Lead Sponsor
Health Institutes of Turkey
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 12 weeks (covering four chemotherapy cycles)
Participants are randomly assigned to use the AI-supported mobile application alongside standard care or to receive standard care alone during chemotherapy. Those using the app will report symptoms daily and receive personalized recommendations while all participants complete assessments at specified times.
Assessments at baseline, after Cycle 1, and after Cycle 4
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Lulu Jiang, Jiehui Xu, Yanwei Wu...
https://pubmed.ncbi.nlm.nih.gov/38833298/Hatice Balci, Saide Faydali
https://pubmed.ncbi.nlm.nih.gov/38969573/Maria Fjell, Ann Langius-Eklöf, Marie Nilsson...
https://pubmed.ncbi.nlm.nih.gov/32247251/Memnun Seven, Şeyma Paşalak, Gulcan Bagcivan...
https://pubmed.ncbi.nlm.nih.gov/36067241/Sharon H Baik, Laura B Oswald, Diana Buitrago...
https://pubmed.ncbi.nlm.nih.gov/32394220/Azza El-Amir, Eman M El-Baiomy, Noha A Sabry...
https://pubmed.ncbi.nlm.nih.gov/37661196/Cvetka Grašič Kuhar, Tjaša Gortnar Cepeda, Timotej Kovač...
https://pubmed.ncbi.nlm.nih.gov/32427567/Ege University
Lead Sponsor
Health Institutes of Turkey
Collaborating Sponsor